Antioxidant effect of short-term hormonal treatment in postmenopausal women.
OBJECTIVE
Recent studies have shown that estrogens alone or in association with progestins can exert an antioxidant effect on Low-Density Lipoprotein (LDL) and lipids of platelet membranes. It has been demonstrated that the oxidative modification of LDLs also involving the formation of lipid peroxides, exerts several biological effects that may contribute to the onset and progression of cardiovascular diseases. Therefore, the aim of our study was to evaluate the effect of short-term treatment with oral estrogens alone and estrogens plus progestin on endogenous and copper-induced serum levels of lipid peroxides in postmenopausal women.


METHODS
Thirty-nine postmenopausal women were randomly divided into three groups: group I was treated with oral conjugated equine estrogens (CEE) for 21 days; group II received oral CEE for 21 days and, after 14 days of this treatment, 5 mg/day of medrogestone was added for 7 days; group III did not receive any therapy (controls). Endogenous and copper-induced serum levels of lipid peroxides were determined before and after 21 days of treatment in the two treated groups and in the control group.


RESULTS
The serum endogenous levels of lipid peroxides in postmenopausal women did not change after short-term treatment with hormone replacement therapy. Moreover, copper-induced serum levels of lipid peroxides significantly decreased after therapy in both groups I and II.


CONCLUSIONS
Our data show that hormone replacement therapy (HRT) inhibits lipid peroxidation and may play a role in preventing cardiovascular diseases.
Clemente
C
C
Laboratory of Biochemistry, Scientific Institute for Digestive Diseases, IRCCS S. De Bellis, Castellana Grotte, Italy.
Caruso
M G
MG
Berloco
P
P
Notarnicola
M
M
D'Attoma
B
B
Osella
A R
AR
Guerra
V
V
Buonsante
A
A
Giannandrea
B
B
Di Leo
A
A
D002318:Cardiovascular Diseases / Q000517:prevention & control*; D019327:Copper Sulfate / Q000494:pharmacology; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology*; D005260:Female; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects*; D008524:Medrogestone / Q000494:pharmacology*; D008875:Middle Aged; D017698:Postmenopause / Q000187:drug effects* / Q000378:metabolism
D004966:Estrogens, Conjugated (USP); D008524:Medrogestone; D019327:Copper Sulfate